Altimmune
ALT | NASDAQ
$1.56
-$0.08 (-5.17%)
At close: Nov 16, 2026, 4:00 PM ET
$1.57
+$0.01 (+0.64%)
After-hours:
Nov 16, 2026, 7:57 PM ET
Altimmune Company Profile
Company profile explainedCompany Profile
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
Key Executives
| Name | Position |
|---|---|
| Jerome Benedict Durso | Chairman, CEO & President |
| Bertrand Georges | Chief Technology Officer |
| Gregory L. Weaver | Chief Financial Officer |
| Robin E. Abrams | Chief Legal Officer & Corporate Secretary |
| Andrew Shutterly | Principal Financial & Accounting Officer and Corporate Controller |
| Christophe Arbet-Engels | Chief Medical Officer |
| Linda Richardson | Chief Commercial Officer |
| Luis Sanay | Vice President of Investor Relations |
| Raymond Jordt | Chief Business Officer |
| Richard Menziuso | VP, Global Controller & Principal Accounting Officer |
| Scot Roberts | Chief Scientific Officer |
| Tony Blandin | Vice President of Quality & Compliance Management |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 29, 2026 | 8-K | Current Report |
| Oct 27, 2026 | 8-K | Current Report |
| Oct 05, 2026 | 4 | Filing |
| Oct 05, 2026 | 4 | Filing |
| Oct 02, 2026 | 4 | Filing |
| Oct 02, 2026 | 3 | Filing |
| Sep 29, 2026 | 8-K | Current Report |
| Sep 17, 2026 | 4 | Filing |
| Aug 13, 2026 | 4 | Filing |
| Aug 12, 2026 | 10-Q | Quarterly Report |
Altimmune
| Country | United States |
| IPO Date | May 26, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 57 |
| CEO | Jerome Benedict Durso |
Contact Details
910 Clopper Road Gaithersburg,
Maryland 20878 United States
Stock Details
| Ticker Symbol | ALT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001326190 |
| CUSIP Number | 02155H200 |
| ISIN Number | US02155H2004 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove ALT